Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
Summary
Illumina is introducing a new distributed whole-genome sequencing solution for molecular residual disease research. The workflow is designed to help labs detect MRD faster and with high sensitivity for both solid tumors and blood cancers. It is available now for early access with select clinical research partners and will expand to global customers next year. The company says the solution is part of a broader oncology portfolio built on NovaSeq X capabilities and DRAGEN analysis. Illumina also points to future updates aimed at even lower detection limits and broader adoption in research settings.
Classifications
industries
Engineering
applications
No applications detected
AskAI Classifications
Labels
Bioinformatics Software
SaaS
Laboratory Informatics
Linked Companies
Illumina
$1B+